Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F97L1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $35,548
Award facts
- Contract value 100% obligated
- $35,548.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $35,548.15 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on January 20, 2026, with an ultimate completion date of January 21, 2026. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed from the awardee's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through DLA. The company maintains an extensive portfolio of federal contract awards covering diverse therapeutic domains including specialty medications, brand-name and generic drugs, vaccines, and medical devices. The DLA Troop Support Medical IDC enables AmerisourceBergen to efficiently fulfill government requirements for essential pharmaceutical commodities needed by military treatment facilities and federal healthcare institutions worldwide. This delivery order for RINVOQ ER, a rheumatoid arthritis medication, exemplifies the company's role in supplying specialized pharmaceutical products to support federal healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F97L1?
SPE2DR26F97L1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F97L1 worth?
The government has obligated $35,548 on SPE2DR26F97L1.
Is contract SPE2DR26F97L1 an order under another contract?
Yes. SPE2DR26F97L1 is a delivery order under SPE2DR25D3505, an indefinite delivery contract.
Was contract SPE2DR26F97L1 competed?
The extent of competition for SPE2DR26F97L1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award